A Structure-activity Relationship Study of Catechol-O-methyltransferase Inhibitors Combining Molecular Docking and 3D QSAR Methods

Overview

Journal J Comput Aided Mol Des

Publisher Springer

Specialties Biomedical Engineering
Molecular Biology

Date 2004 May 6

PMID 15124929

Citations 7

Authors

Anu J Tervo

Tommi H Nyronen

Toni Ronkko

Antti Poso

Affiliations

Soon will be listed here.

Abstract

A panel of 92 catechol-O-methyltransferase (COMT) inhibitors was used to examine the molecular interactions affecting their biological activity. COMT inhibitors are used as therapeutic agents in the treatment of Parkinson's disease, but there are limitations in the currently marketed compounds due to adverse side effects. This study combined molecular docking methods with three-dimensional structure-activity relationships (3D QSAR) to analyse possible interactions between COMT and its inhibitors, and to incite the design of new inhibitors. Comparative molecular field analysis (CoMFA) and GRID/GOLPE models were made by using bioactive conformations from docking experiments, which yielded q2 values of 0.594 and 0.636, respectively. The docking results, the COMT X-ray structure, and the 3D QSAR models are in agreement with each other. The models suggest that an interaction between the inhibitor's catechol oxygens and the Mg2+ ion in the COMT active site is important. Both hydrogen bonding with Lys144, Asn170 and Glu199, and hydrophobic contacts with Trp38, Pro174 and Leu198 influence inhibitor binding. Docking suggests that a large R1 substituent of the catechol ring can form hydrophobic contacts with side chains of Val173, Leu198, Met201 and Val203 on the COMT surface. Our models propose that increasing steric volume of e.g. the diethylamine tail of entacapone is favourable for COMT inhibitory activity.

Citing Articles

Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.

Wang X, Wang Y, Li X, Yu Z, Song C, Du Y RSC Med Chem. 2021; 12(10):1650-1671.

PMID: 34778767 PMC: 8528211. DOI: 10.1039/d1md00131k.

Computational Studies Applied to Flavonoids against Alzheimer's and Parkinson's Diseases.

Monteiro A, de O Viana J, Nayarisseri A, Zondegoumba E, Mendonca Junior F, Scotti M Oxid Med Cell Longev. 2019; 2018:7912765.

PMID: 30693065 PMC: 6332933. DOI: 10.1155/2018/7912765.

(E)-Ethyl 2-cyano-3-(3,4-dihydr-oxy-5-nitro-phen-yl)acrylate.

Zhang S, Zheng X, Hu W Acta Crystallogr Sect E Struct Rep Online. 2011; 65(Pt 10):o2351.

PMID: 21577820 PMC: 2970386. DOI: 10.1107/S1600536809035132.

Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Fleming F, Yao L, Ravikumar P, Funk L, Shook B J Med Chem. 2010; 53(22):7902-17.

PMID: 20804202 PMC: 2988972. DOI: 10.1021/jm100762r.

Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.

Kinnings S, Liu N, Buchmeier N, Tonge P, Xie L, Bourne P PLoS Comput Biol. 2009; 5(7):e1000423.

PMID: 19578428 PMC: 2699117. DOI: 10.1371/journal.pcbi.1000423.

References

Mannisto P, Kaakkola S . Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999; 51(4):593-628. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Oprea T, Garcia A . Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors. J Comput Aided Mol Des. 1996; 10(3):186-200. DOI: 10.1007/BF00355042. View

Guldberg H, Marsden C . Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975; 27(2):135-206. View

Micek S, Ernst M . Tolcapone: a novel approach to Parkinson's disease. Am J Health Syst Pharm. 1999; 56(21):2195-205. DOI: 10.1093/ajhp/56.21.2195. View

Buolamwini J, Assefa H . CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem. 2002; 45(4):841-52. DOI: 10.1021/jm010399h. View

Bonifati V, Meco G . New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther. 1999; 81(1):1-36. DOI: 10.1016/s0163-7258(98)00032-1. View

Pastor M, Cruciani G, Clementi S . Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. J Med Chem. 1997; 40(10):1455-64. DOI: 10.1021/jm9608016. View

Sippl W . Receptor-based 3D QSAR analysis of estrogen receptor ligands--merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J Comput Aided Mol Des. 2000; 14(6):559-72. DOI: 10.1023/a:1008115913787. View

10.

Lotta T, Taskinen J, Backstrom R, Nissinen E . PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors. J Comput Aided Mol Des. 1992; 6(3):253-72. DOI: 10.1007/BF00123380. View

11.

Gordin A, Kaakkola S, Teravainen H . Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol. 2002; 91:237-50. View

12.

Bohm H . The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput Aided Mol Des. 1994; 8(3):243-56. DOI: 10.1007/BF00126743. View

13.

Olanow C . Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol. 2000; 57(2):263-7. DOI: 10.1001/archneur.57.2.263. View

14.

Liu H, Huang X, Shen J, Luo X, Li M, Xiong B . Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses. J Med Chem. 2002; 45(22):4816-27. DOI: 10.1021/jm020089e. View

15.

De Santi C, Giulianotti P, Pietrabissa A, Mosca F, Pacifici G . Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. Eur J Clin Pharmacol. 1998; 54(3):215-9. DOI: 10.1007/s002280050448. View

16.

Lehtonen J, Still D, Rantanen V, Ekholm J, Bjorklund D, Iftikhar Z . BODIL: a molecular modeling environment for structure-function analysis and drug design. J Comput Aided Mol Des. 2005; 18(6):401-19. DOI: 10.1007/s10822-004-3752-4. View

17.

Vidgren J, Svensson L, Liljas A . Crystal structure of catechol O-methyltransferase. Nature. 1994; 368(6469):354-8. DOI: 10.1038/368354a0. View

18.

Cramer R, Patterson D, Bunce J . Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc. 2011; 110(18):5959-67. DOI: 10.1021/ja00226a005. View

19.

Guttman M, Leger G, Reches A, Evans A, Kuwabara H, Cedarbaum J . Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord. 1993; 8(3):298-304. DOI: 10.1002/mds.870080308. View

20.

Axelrod J, TOMCHICK R . Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958; 233(3):702-5. View